JP6901975B2 - 注射デバイスに取り付けられるデータ収集装置 - Google Patents
注射デバイスに取り付けられるデータ収集装置 Download PDFInfo
- Publication number
- JP6901975B2 JP6901975B2 JP2017564021A JP2017564021A JP6901975B2 JP 6901975 B2 JP6901975 B2 JP 6901975B2 JP 2017564021 A JP2017564021 A JP 2017564021A JP 2017564021 A JP2017564021 A JP 2017564021A JP 6901975 B2 JP6901975 B2 JP 6901975B2
- Authority
- JP
- Japan
- Prior art keywords
- data acquisition
- acquisition device
- dose
- injection device
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002347 injection Methods 0.000 title claims description 229
- 239000007924 injection Substances 0.000 title claims description 229
- 239000003814 drug Substances 0.000 claims description 89
- 229940079593 drug Drugs 0.000 claims description 88
- 230000006870 function Effects 0.000 claims description 37
- 230000033001 locomotion Effects 0.000 claims description 33
- 230000003287 optical effect Effects 0.000 claims description 20
- 238000001647 drug administration Methods 0.000 claims description 12
- 230000001960 triggered effect Effects 0.000 claims description 5
- 238000013480 data collection Methods 0.000 claims description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 41
- 239000002775 capsule Substances 0.000 description 28
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 22
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 21
- 108090001061 Insulin Proteins 0.000 description 19
- 102000004877 Insulin Human genes 0.000 description 19
- 229940125396 insulin Drugs 0.000 description 19
- 230000004913 activation Effects 0.000 description 11
- 230000005540 biological transmission Effects 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 8
- 108010011459 Exenatide Proteins 0.000 description 8
- 238000012377 drug delivery Methods 0.000 description 8
- 238000003825 pressing Methods 0.000 description 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- -1 human insulin Chemical compound 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical class [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 description 5
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000004891 communication Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 4
- 208000002249 Diabetes Complications Diseases 0.000 description 4
- 108010019598 Liraglutide Proteins 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229920001971 elastomer Polymers 0.000 description 4
- 229960001519 exenatide Drugs 0.000 description 4
- 229940127560 insulin pen Drugs 0.000 description 4
- 229960002701 liraglutide Drugs 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 102000009109 Fc receptors Human genes 0.000 description 3
- 108010087819 Fc receptors Proteins 0.000 description 3
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 3
- 102000006771 Gonadotropins Human genes 0.000 description 3
- 108010086677 Gonadotropins Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000002783 friction material Substances 0.000 description 3
- 239000002622 gonadotropin Substances 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000003055 low molecular weight heparin Substances 0.000 description 3
- 229940127215 low-molecular weight heparin Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000005060 rubber Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical group OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 208000001435 Thromboembolism Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 230000004397 blinking Effects 0.000 description 2
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000013013 elastic material Substances 0.000 description 2
- 210000003811 finger Anatomy 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108091060283 mipomersen Proteins 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 229960004532 somatropin Drugs 0.000 description 2
- 210000003813 thumb Anatomy 0.000 description 2
- MSFZPBXAGPYVFD-NFBCFJMWSA-N (2r)-2-amino-3-[1-[3-[2-[2-[2-[4-[[(5s)-5,6-diamino-6-oxohexyl]amino]butylamino]-2-oxoethoxy]ethoxy]ethylamino]-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoic acid Chemical compound NC(=O)[C@@H](N)CCCCNCCCCNC(=O)COCCOCCNC(=O)CCN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O MSFZPBXAGPYVFD-NFBCFJMWSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- URRAHSMDPCMOTH-LNLFQRSKSA-N Denagliptin Chemical compound C=1C=C(F)C=CC=1C([C@H](N)C(=O)N1[C@@H](C[C@H](F)C1)C#N)C1=CC=C(F)C=C1 URRAHSMDPCMOTH-LNLFQRSKSA-N 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 230000005355 Hall effect Effects 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010057186 Insulin Glargine Proteins 0.000 description 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229960004733 albiglutide Drugs 0.000 description 1
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 description 1
- 229960004539 alirocumab Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000004323 axial length Effects 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 229940014641 bydureon Drugs 0.000 description 1
- 229940084891 byetta Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- TZRFSLHOCZEXCC-HIVFKXHNSA-N chembl2219536 Chemical compound N1([C@H]2C[C@@H]([C@H](O2)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C(C)=C2)=O)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2CO)N2C3=C(C(NC(N)=N3)=O)N=C2)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(NC(=O)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP(O)(=O)OC[C@H]2O[C@H](C[C@@H]2SP(O)(=O)OC[C@H]2O[C@H](C[C@@H]2SP(O)(=O)OC[C@H]2O[C@H](C[C@@H]2SP(O)(=O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OCCOC)SP(O)(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP(O)(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C3=NC=NC(N)=C3N=C2)OCCOC)SP(O)(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP(O)(=O)OC[C@H]2[C@H](O)[C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)C=C(C)C(N)=NC1=O TZRFSLHOCZEXCC-HIVFKXHNSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 229950010300 denagliptin Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229950003468 dupilumab Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 229960005153 enoxaparin sodium Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 229960002869 insulin glargine Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940098262 kynamro Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960001093 lixisenatide Drugs 0.000 description 1
- 108010004367 lixisenatide Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 229960004778 mipomersen Drugs 0.000 description 1
- OSGPYAHSKOGBFY-KMHHXCEHSA-A mipomersen sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].N1([C@H]2C[C@@H]([C@H](O2)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C(C)=C2)=O)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2CO)N2C3=C(C(NC(N)=N3)=O)N=C2)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(NC(=O)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP([O-])(=O)OC[C@H]2O[C@H](C[C@@H]2SP([O-])(=O)OC[C@H]2O[C@H](C[C@@H]2SP([O-])(=O)OC[C@H]2O[C@H](C[C@@H]2SP([O-])(=O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OCCOC)SP([O-])(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP([O-])(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C3=NC=NC(N)=C3N=C2)OCCOC)SP([O-])(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP([O-])(=O)OC[C@H]2[C@H](O)[C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)C=C(C)C(N)=NC1=O OSGPYAHSKOGBFY-KMHHXCEHSA-A 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 238000012015 optical character recognition Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108700027806 rGLP-1 Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 229950006348 sarilumab Drugs 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 229940036220 synvisc Drugs 0.000 description 1
- CIJQTPFWFXOSEO-NDMITSJXSA-J tetrasodium;(2r,3r,4s)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(1r,2r,3r,4r)-4-[(2r,3s,4r,5r,6r)-5-acetamido-6-[(4r,5r,6r)-2-carboxylato-4,5-dihydroxy-6-[[(1r,3r,4r,5r)-3-hydroxy-4-(sulfonatoamino)-6,8-dioxabicyclo[3.2.1]octan-2-yl]oxy]oxan-3-yl]oxy-2-(hydroxy Chemical compound [Na+].[Na+].[Na+].[Na+].O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1O)NC(C)=O)O[C@@H]1C(C[C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H](CO)O[C@H](OC2C(O[C@@H](OC3[C@@H]([C@@H](NS([O-])(=O)=O)[C@@H]4OC[C@H]3O4)O)[C@H](O)[C@H]2O)C([O-])=O)[C@H](NC(C)=O)[C@H]1C)C([O-])=O)[C@@H]1OC(C([O-])=O)=C[C@H](O)[C@H]1O CIJQTPFWFXOSEO-NDMITSJXSA-J 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31533—Dosing mechanisms, i.e. setting a dose
- A61M5/31545—Setting modes for dosing
- A61M5/31548—Mechanically operated dose setting member
- A61M5/3155—Mechanically operated dose setting member by rotational movement of dose setting member, e.g. during setting or filling of a syringe
- A61M5/31551—Mechanically operated dose setting member by rotational movement of dose setting member, e.g. during setting or filling of a syringe including axial movement of dose setting member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31525—Dosing
- A61M5/31528—Dosing by means of rotational movements, e.g. screw-thread mechanisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31576—Constructional features or modes of drive mechanisms for piston rods
- A61M5/31583—Constructional features or modes of drive mechanisms for piston rods based on rotational translation, i.e. movement of piston rod is caused by relative rotation between the user activated actuator and the piston rod
- A61M5/31585—Constructional features or modes of drive mechanisms for piston rods based on rotational translation, i.e. movement of piston rod is caused by relative rotation between the user activated actuator and the piston rod performed by axially moving actuator, e.g. an injection button
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3125—Details specific display means, e.g. to indicate dose setting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3125—Details specific display means, e.g. to indicate dose setting
- A61M2005/3126—Specific display means related to dosing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3306—Optical measuring means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/502—User interfaces, e.g. screens or keyboards
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/52—General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/581—Means for facilitating use, e.g. by people with impaired vision by audible feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback
- A61M2205/584—Means for facilitating use, e.g. by people with impaired vision by visual feedback having a color code
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/587—Lighting arrangements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/82—Internal energy supply devices
- A61M2205/8206—Internal energy supply devices battery-operated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Description
Claims (27)
- データ収集デバイスであって:
第1の部分であって、第1の部分の内面は、注射デバイスの投与量ノブの表面の構造に対応し、かつ、嵌まるように構成された溝を含む第1の部分と;
第2の部分であって、該第1の部分が第2の部分に対して回転するように構成されている第2の部分と;
該第2の部分に対する第1の部分の回転を検出するように構成されたセンサ配置であって、該センサ配置が第2の部分によって支持されており、該センサ配置が第1の部分の回転を直接検出するように構成されているセンサ配置と;
前記検出された回転に基づいて、注射デバイスによって排出される薬剤量を決定するように構成されたプロセッサ配置と
を含む前記データ収集デバイス。 - センサ配置は、第2の部分に対する回転が固定され、薬剤が注射デバイスによって排出されるとき第2の部分と共に回転する、請求項1に記載のデータ収集デバイス。
- 第1の部分は第2の部分に回転可能に取り付けられる、請求項1に記載のデータ収集デバイス。
- 第2の部分は第1の電気接点を有する外側部分を含み;
第2の部分は第2の電気接点を有する内側部分を含み;
該内側部分は外側部分に対して軸方向に可動であり、圧力が外側部分に加えられたとき前記第1の電気接点を前記第2の電気接点に係合させる、請求項3に記載のデータ収集デバイス。 - 前記第1の電気接点が第2の電気接点に係合、または、非係合のいずれか一方、または、両方であるときトリガするように構成されるタイマを含む、請求項4に記載のデータ収集デバイス。
- プロセッサ配置は、前記タイマが最後にトリガされてからの経過時間を判定し、経過時間が閾値条件に合わない場合に警報を発するように構成される、請求項5に記載のデータ収集デバイス。
- プロセッサ配置は、前記タイマを使用して薬剤の投与のためのタイムスタンプを判定し、判定された薬剤量および前記タイムスタンプを記憶するように構成される、請求項5に記載のデータ収集デバイス。
- プロセッサ配置は、判定された薬剤量のログおよび対応するタイムスタンプに関連する情報を別のデバイスに送信するように構成される、請求項7に記載のデータ収集デバイス。
- データ収集デバイスは、第2の部分に対する第1の部分の回転が防止される第1の構成と、第1の部分が第2の部分に対して回転可能な第2の構成との間で切り替わるように構成される、請求項1に記載のデータ収集デバイス。
- センサ配置は、光学センサ、磁気センサ、容量センサ、および機械センサのうちの1つまたはそれ以上を含む、請求項1に記載のデータ収集デバイス。
- 第1の部分に1つまたはそれ以上の外側グリップ機能を設けて、ユーザによる第1の部分の把持を容易にすることにより、注射デバイスのハウジングに対してデータ収集デバイスを回転させる、請求項1に記載のデータ収集デバイス。
- 第1の部分のユーザが接触可能な表面は、データ収集デバイスが注射デバイスに装着されたときに、第1の部分のユーザが接触可能な表面は、第2の部分のユーザが接触可能な部分よりも大きい、請求項1に記載のデータ収集デバイス。
- 第2の部分は、データ収集デバイスの外径よりもデータ収集デバイスの長手方向軸に半径方向に近い位置で、第1の部分に回転可能に連結される、請求項1に記載のデータ収集デバイス。
- 第1の部分は、データ収集デバイスが注射デバイスに連結されたときに注射デバイスの用量ボタンの周りに少なくとも部分的に密に嵌合するように構成された要素を含む、請求項1に記載のデータ収集デバイス。
- 薬剤投与装置であって:
薬剤が注射デバイスから排出されるときに回転するように構成された投与量ノブと、注射デバイスから薬剤を排出させるように構成された注射ボタンを含む注射デバイスと;
請求項1に記載のデータ収集デバイスとを含む前記薬剤投与装置。 - データ収集デバイスの第2の部分は、第2の部分に圧力が加えられたときに用量ボタンを押すように配置される、請求項15に記載の薬剤投与装置。
- データ収集デバイスであって、
データ収集デバイスを注射デバイスの投与量ノブに取り付けるように構成された1つまたはそれ以上の機能を有する第1の部分であって、特に、第1の部分の内面は、注射デバイスの投与量ノブの表面の構造に対応し、かつ、嵌まるように構成された溝を含む第1の部分と;
第1の部分に回転可能に取り付けられ、注射デバイスの用量ボタンと係合するように構
成されている第2の部分と;
注射デバイスによる薬剤の排出中に第2の部分に対する第1の部分の回転を検出するように構成されたセンサ配置であって、センサ配置が第2の部分によって支持され、センサ配置が第1の部分の回転を直接検出するように構成されている、センサ配置と;
検出された動きに基づいて注射デバイスによって排出される薬剤量を決定するように構成されたプロセッサ配置と
を含む前記データ収集デバイス。 - センサ配置は、第2の部分に対する回転が固定され、薬剤が注射デバイスによって排出されるとき第2の部分と共に回転する、請求項17に記載のデータ収集デバイス。
- データ収集デバイスを注射デバイスの投与量ノブに取り付けるように構成された1つまたはそれ以上の機能は、第1の部分と注射デバイスの投与量ノブとの非恒久的連結をもたらすように構成される、請求項17に記載のデータ収集デバイス。
- 第2の部分のユーザが接触可能な表面は、データ収集デバイスが注射デバイスに装置されたときに、第1の部分のユーザが接触可能な部分よりも大きい、請求項17に記載のデータ収集デバイス。
- 第2の部分は、データ収集デバイスの外径よりもデータ収集デバイスの長手方向軸から半径方向に遠い位置で、第1の部分に回転可能に連結される、請求項17に記載のデータ収集デバイス。
- データ収集デバイスは、第2の部分に対する第1の部分の回転が防止される第1の構成と、第1の部分が第2の部分に対して回転可能な第2の構成との間で切り替わるように構成される、請求項17に記載のデータ収集デバイス。
- 第2の部分の少なくとも一部は、第1の部分に対して軸方向に可動である、請求項17に記載のデータ収集デバイス。
- センサ配置は、光学センサを含む、請求項17に記載のデータ収集デバイス。
- 第1の部分に対して第2の部分の少なくとも一部が動いたときに動作するように構成された電気スイッチをさらに含み、電気スイッチを動作させるために必要な力は、注射デバイスから薬剤を送達するのに必要な力よりも小さい、請求項17に記載のデータ収集デバイス。
- 薬剤投与装置であって:
薬剤が注射デバイスから排出されるときに回転するように構成された投与量ノブと、注射デバイスから薬剤を排出させるように配置された用量ボタンとを含む注射デバイスと;
請求項17に記載のデータ収集デバイスとを含む前記薬剤投与装置。 - データ収集デバイスの第2の部分は、圧力が第2の部分に加えられたとき用量ボタンを押すように配置される、請求項26に記載の薬剤投与装置。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021037904A JP7162093B2 (ja) | 2015-06-09 | 2021-03-10 | 注射デバイスに取り付けられるデータ収集装置 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15171252.8 | 2015-06-09 | ||
EP15171252.8A EP3103492A1 (en) | 2015-06-09 | 2015-06-09 | Data collection apparatus for attachment to an injection device |
EP15199308.6 | 2015-12-10 | ||
EP15199308 | 2015-12-10 | ||
PCT/EP2016/063139 WO2016198516A1 (en) | 2015-06-09 | 2016-06-09 | Data collection apparatus for attachment to an injection device |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021037904A Division JP7162093B2 (ja) | 2015-06-09 | 2021-03-10 | 注射デバイスに取り付けられるデータ収集装置 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018517502A JP2018517502A (ja) | 2018-07-05 |
JP6901975B2 true JP6901975B2 (ja) | 2021-07-14 |
Family
ID=56131518
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017564021A Active JP6901975B2 (ja) | 2015-06-09 | 2016-06-09 | 注射デバイスに取り付けられるデータ収集装置 |
JP2021037904A Active JP7162093B2 (ja) | 2015-06-09 | 2021-03-10 | 注射デバイスに取り付けられるデータ収集装置 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021037904A Active JP7162093B2 (ja) | 2015-06-09 | 2021-03-10 | 注射デバイスに取り付けられるデータ収集装置 |
Country Status (10)
Country | Link |
---|---|
US (7) | US10874802B2 (ja) |
EP (3) | EP4316552A3 (ja) |
JP (2) | JP6901975B2 (ja) |
CN (3) | CN107787236B (ja) |
DK (1) | DK3307357T4 (ja) |
ES (1) | ES2805230T5 (ja) |
HK (1) | HK1248622A1 (ja) |
HU (1) | HUE050055T2 (ja) |
PL (1) | PL3307357T5 (ja) |
WO (1) | WO2016198516A1 (ja) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012127046A2 (en) | 2011-03-24 | 2012-09-27 | Sanofi-Aventis Deutschland Gmbh | Device and method for detecting an actuation action performable with a medical device |
BR112017011213A2 (pt) | 2014-12-23 | 2018-02-14 | Automed Pty Ltd | aparelho de fornecimento, sistema e métodos associados |
EP3058970A1 (en) | 2015-02-19 | 2016-08-24 | Sanofi-Aventis Deutschland GmbH | Data collection device for attachment to an injection device |
EP4316552A3 (en) | 2015-06-09 | 2024-04-17 | Sanofi-Aventis Deutschland GmbH | Data collection apparatus for attachment to an injection device |
US10864327B2 (en) | 2016-01-29 | 2020-12-15 | Companion Medical, Inc. | Automatic medication delivery tracking |
US10892525B2 (en) * | 2016-06-29 | 2021-01-12 | University Of Kentucky Research Foundation | Rechargeable batteries including high-voltage cathode and redox shuttle conferring overcharge protection |
US11554221B2 (en) * | 2016-07-15 | 2023-01-17 | Eli Lilly And Company | Dose detection module for a medication delivery device |
CN114099856A (zh) | 2016-09-09 | 2022-03-01 | 赛诺菲-安万特德国有限公司 | 附接至注射装置的数据收集设备 |
CN110248688B (zh) | 2016-12-07 | 2022-03-11 | 赛诺菲 | 用于附接至注射装置的数据收集装置 |
JP7084412B2 (ja) | 2017-02-28 | 2022-06-14 | イーライ リリー アンド カンパニー | 薬物送達装置のための用量検出および薬物識別 |
KR20190005572A (ko) * | 2017-07-07 | 2019-01-16 | 최규동 | 펜형 주사장치의 범용 장착형 투입량 측정 및 관리 시스템 |
US20190022330A1 (en) * | 2017-07-21 | 2019-01-24 | Verily Life Sciences Llc | Strain based dosage measurement |
WO2019036576A1 (en) * | 2017-08-18 | 2019-02-21 | Eli Lilly And Company | DOSING MEASUREMENT MODULE ON INJECTION PEN |
CA3073605C (en) * | 2017-08-21 | 2023-03-21 | Eli Lilly And Company | Medication delivery device with sensing system |
PL3684447T3 (pl) | 2017-09-22 | 2022-10-24 | Novo Nordisk A/S | Urządzenie dodatkowe do urządzenia dostarczającego lek |
US11672913B2 (en) | 2017-10-06 | 2023-06-13 | Sanofi | Data collection device |
US20200276393A1 (en) * | 2017-10-19 | 2020-09-03 | Sanofi | A medicament administration device and data collection device |
CN117653830A (zh) * | 2017-11-23 | 2024-03-08 | 赛诺菲 | 具有旋转编码器的药剂注射装置 |
EP3495008A1 (en) * | 2017-12-06 | 2019-06-12 | Sanofi | Wind-up servo-actuator and drug delivery device |
US10987464B2 (en) | 2017-12-12 | 2021-04-27 | Bigfoot Biomedical, Inc. | Pen cap for insulin injection pens and associated methods and systems |
US11083852B2 (en) | 2017-12-12 | 2021-08-10 | Bigfoot Biomedical, Inc. | Insulin injection assistance systems, methods, and devices |
US11464459B2 (en) | 2017-12-12 | 2022-10-11 | Bigfoot Biomedical, Inc. | User interface for diabetes management systems including flash glucose monitor |
US11116899B2 (en) | 2017-12-12 | 2021-09-14 | Bigfoot Biomedical, Inc. | User interface for diabetes management systems and devices |
US11077243B2 (en) | 2017-12-12 | 2021-08-03 | Bigfoot Biomedical, Inc. | Devices, systems, and methods for estimating active medication from injections |
EP3724889A2 (en) | 2017-12-12 | 2020-10-21 | Bigfoot Biomedical, Inc. | Therapy assist information and/or tracking device and related methods and systems |
JP2021506478A (ja) * | 2017-12-20 | 2021-02-22 | サノフイSanofi | 注射デバイスに取り付けるためのデバイス |
JP2021508555A (ja) * | 2017-12-28 | 2021-03-11 | サノフイSanofi | 注射デバイスに取り付けるためのデータ収集装置 |
EP3517153A1 (en) * | 2018-01-24 | 2019-07-31 | Insulcloud, S.L. | Monitoring device with universal adapter to drug injection pens |
WO2019162235A1 (en) | 2018-02-20 | 2019-08-29 | Novo Nordisk A/S | Accessory device with mounting feature for engaging dial member |
CA3090539C (en) | 2018-02-22 | 2023-08-22 | Eli Lilly And Company | Dose detection system module for medication delivery device |
IL277627B1 (en) * | 2018-03-26 | 2024-04-01 | Patients Pending Ltd | Capping devices, systems and methods for liquid delivery devices |
CN109157714A (zh) * | 2018-04-24 | 2019-01-08 | 无锡市人民医院 | 一种自动报数的有声胰岛素笔 |
US11185636B2 (en) | 2018-07-26 | 2021-11-30 | Verily Life Sciences Llc | Electrostatic rotary encoder |
CN112584884B (zh) * | 2018-08-15 | 2023-04-04 | 赛诺菲 | 用于附接至注射装置的数据收集设备 |
USD914199S1 (en) | 2018-08-29 | 2021-03-23 | Eli Lilly And Company | Component for a drug delivery device |
USD903857S1 (en) | 2018-08-29 | 2020-12-01 | Eli Lilly And Company | Component for a drug delivery device |
USD903105S1 (en) | 2018-08-29 | 2020-11-24 | Eli Lilly And Company | Component for a drug delivery device |
USD903858S1 (en) | 2018-08-29 | 2020-12-01 | Eli Lilly And Company | Drug delivery device |
US11229749B2 (en) * | 2018-09-06 | 2022-01-25 | Verily Life Sciences Llc | Plate capacitor for dosage sensing |
CA3111288A1 (en) * | 2018-09-12 | 2020-03-19 | Becton, Dickinson And Company | Universal connection device for pen injectors |
JP7440510B2 (ja) * | 2018-11-23 | 2024-02-28 | サノフイ | 注射デバイスのための補助デバイス |
US20220001110A1 (en) * | 2018-12-04 | 2022-01-06 | Novo Nordisk A/S | Drug delivery assembly with moving sensor system |
EA039601B1 (ru) * | 2018-12-14 | 2022-02-15 | Эли Лилли Энд Компани | Модуль системы определения дозы для устройства доставки лекарственного препарата |
KR102194269B1 (ko) * | 2018-12-31 | 2020-12-22 | 권기만 | 투여량 측정 및 관리가 가능한 펜형 주사장치의 휴대용 냉장 보관 케이스 시스템 |
US11948671B2 (en) | 2019-04-11 | 2024-04-02 | Medtronic Minimed, Inc. | Intelligent accessories for medicine dispensing device |
WO2020217076A1 (en) * | 2019-04-26 | 2020-10-29 | Biocorp Production S.A. | Injection monitoring module |
WO2020249776A1 (en) * | 2019-06-13 | 2020-12-17 | Sanofi | Apparatus for detecting a dose of medicament delivered from an injection device |
CN110624160B (zh) * | 2019-10-21 | 2020-11-13 | 北京糖护科技有限公司 | 数字化高精度胰岛素笔注射数据采集装置 |
PL431693A1 (pl) * | 2019-10-31 | 2021-05-04 | Copernicus Spółka Z Ograniczoną Odpowiedzialnością | Urządzenie do podawania leku z układem do pomiaru dawki ustawionej lub dawki podanej |
US20220395641A1 (en) * | 2019-11-14 | 2022-12-15 | Sanofi | A wireless data communication accessory for a drug delivery device |
WO2021116052A1 (en) * | 2019-12-09 | 2021-06-17 | Sanofi | A drug delivery device |
TWI777138B (zh) * | 2020-03-02 | 2022-09-11 | 廣達電腦股份有限公司 | 胰島素劑量偵測裝置 |
US11957542B2 (en) | 2020-04-30 | 2024-04-16 | Automed Patent Holdco, Llc | Sensing complete injection for animal injection device |
EP4168069A1 (en) * | 2020-06-23 | 2023-04-26 | Biocorp Production S.A. | Injection monitoring module |
KR102284455B1 (ko) * | 2021-02-18 | 2021-08-02 | 주식회사 바로메디 | 약물 주입기 관리용 시스템 |
WO2023018695A1 (en) * | 2021-08-09 | 2023-02-16 | Create To Overcome Llc | Acoustic dose meter |
CN116672544A (zh) * | 2022-02-22 | 2023-09-01 | 上海微创生命科技有限公司 | 注射量采集装置及胰岛素注射系统 |
Family Cites Families (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US533575A (en) | 1895-02-05 | wilkens | ||
CH675078A5 (ja) | 1988-01-22 | 1990-08-31 | Nosta Ag | |
US4959056A (en) | 1988-06-14 | 1990-09-25 | Wayne State University | Digital dispenser |
DK68789A (da) | 1989-02-14 | 1990-08-15 | Novo Nordisk As | Injektionspen |
SE466684B (sv) | 1989-03-07 | 1992-03-23 | Draco Ab | Anordning vid en inhalator samt foerfarande foer att med anordningen registrera medicinering med inhalator |
US5226895A (en) | 1989-06-05 | 1993-07-13 | Eli Lilly And Company | Multiple dose injection pen |
GB9007113D0 (en) | 1990-03-29 | 1990-05-30 | Sams Bernard | Dispensing device |
DK0525525T3 (da) | 1991-07-24 | 1995-10-02 | Medico Dev Investment Co | Injektor |
DK175491D0 (da) | 1991-10-18 | 1991-10-18 | Novo Nordisk As | Apparat |
US5279586A (en) | 1992-02-04 | 1994-01-18 | Becton, Dickinson And Company | Reusable medication delivery pen |
CH682805A5 (de) | 1992-02-24 | 1993-11-30 | Medimpex Ets | Anzeigeeinrichtung für ein Injektionsgerät. |
US5320609A (en) | 1992-12-07 | 1994-06-14 | Habley Medical Technology Corporation | Automatic pharmaceutical dispensing syringe |
US5383865A (en) | 1993-03-15 | 1995-01-24 | Eli Lilly And Company | Medication dispensing device |
ZA941881B (en) | 1993-04-02 | 1995-09-18 | Lilly Co Eli | Manifold medication injection apparatus and method |
CA2129284C (en) | 1993-11-24 | 1999-03-09 | Kenneth J. Niehoff | Controlling plunger drives for fluid injection in animals |
US5536249A (en) | 1994-03-09 | 1996-07-16 | Visionary Medical Products, Inc. | Pen-type injector with a microprocessor and blood characteristic monitor |
US5582598A (en) | 1994-09-19 | 1996-12-10 | Becton Dickinson And Company | Medication delivery pen with variable increment dose scale |
CA2213682C (en) | 1995-03-07 | 2009-10-06 | Eli Lilly And Company | Recyclable medication dispensing device |
US6246322B1 (en) | 1995-12-26 | 2001-06-12 | Headwaters Research & Development, Inc. | Impulse characteristic responsive missing object locator operable in noisy environments |
US5674204A (en) | 1995-09-19 | 1997-10-07 | Becton Dickinson And Company | Medication delivery pen cap actuated dose delivery clutch |
US5688251A (en) | 1995-09-19 | 1997-11-18 | Becton Dickinson And Company | Cartridge loading and priming mechanism for a pen injector |
IL125838A (en) | 1996-02-23 | 2003-10-31 | Novo Nordisk As | Syringe with electronic representation of parameters |
EP1015050A1 (en) | 1997-07-11 | 2000-07-05 | Novo Nordisk A/S | An apparatus for the registration of the setting of a medical device |
DE19730999C1 (de) | 1997-07-18 | 1998-12-10 | Disetronic Licensing Ag | Dosierknopfsicherung an einer Vorrichtung zur dosierten Verabreichung eines injizierbaren Produkts |
US5921966A (en) | 1997-08-11 | 1999-07-13 | Becton Dickinson And Company | Medication delivery pen having an improved clutch assembly |
CH692543A5 (de) | 1997-09-25 | 2002-07-31 | Disetronic Licensing Ag | Abgabevorrichtung mit Signalgeber. |
CA2305634C (en) | 1998-01-30 | 2006-01-03 | Novo Nordisk A/S | An injection syringe |
US6096010A (en) | 1998-02-20 | 2000-08-01 | Becton, Dickinson And Company | Repeat-dose medication delivery pen |
US6221053B1 (en) | 1998-02-20 | 2001-04-24 | Becton, Dickinson And Company | Multi-featured medication delivery pen |
US6248095B1 (en) | 1998-02-23 | 2001-06-19 | Becton, Dickinson And Company | Low-cost medication delivery pen |
JPH11267207A (ja) * | 1998-03-24 | 1999-10-05 | Miyota Kk | 携帯型注射器 |
US7193521B2 (en) | 1998-10-29 | 2007-03-20 | Medtronic Minimed, Inc. | Method and apparatus for detecting errors, fluid pressure, and occlusions in an ambulatory infusion pump |
DE29904864U1 (de) | 1999-03-17 | 2000-08-03 | Braun Melsungen Ag | Injektionsvorrichtung mit einem Pen |
DE60026147T2 (de) | 1999-08-05 | 2006-11-23 | Becton, Dickinson And Co. | Stiftförmige medikamentenabgabevorrichtung |
US6277099B1 (en) | 1999-08-06 | 2001-08-21 | Becton, Dickinson And Company | Medication delivery pen |
US6585698B1 (en) | 1999-11-01 | 2003-07-01 | Becton, Dickinson & Company | Electronic medical delivery pen having a multifunction actuator |
GB0007071D0 (en) | 2000-03-24 | 2000-05-17 | Sams Bernard | One-way clutch mechanisms and injector devices |
US6500169B1 (en) | 2000-05-15 | 2002-12-31 | Stryker Corporation | Powered surgical handpiece with membrane switch |
WO2001091098A1 (fr) | 2000-05-24 | 2001-11-29 | Hitachi, Ltd. | Terminal portable et afficheur commutable entre couleur et noir-et-blanc |
JP2001357132A (ja) | 2000-06-12 | 2001-12-26 | Iwami Kaihatsu Kk | 医薬品の投与システム及び投与方法 |
US6663602B2 (en) | 2000-06-16 | 2003-12-16 | Novo Nordisk A/S | Injection device |
IL156245A0 (en) | 2000-12-22 | 2004-01-04 | Dca Design Int Ltd | Drive mechanism for an injection device |
US6899699B2 (en) | 2001-01-05 | 2005-05-31 | Novo Nordisk A/S | Automatic injection device with reset feature |
JP4278382B2 (ja) | 2001-02-14 | 2009-06-10 | ノボ ノルディスク アクティーゼルスカブ | 電子制御される注射器即ち注入装置 |
US7044933B2 (en) | 2001-03-01 | 2006-05-16 | Scimed Life Systems, Inc. | Fluid injection system for coronary intervention |
US20050192530A1 (en) | 2001-04-13 | 2005-09-01 | Penjet Corporation | Method and apparatus for needle-less injection with a degassed fluid |
US6817986B2 (en) | 2001-04-13 | 2004-11-16 | Avant Medical Corp. | Jet injector with data logging system for use in compliance and dose monitoring programs |
US7195616B2 (en) | 2001-05-16 | 2007-03-27 | Eli Lilly And Company | Medication injector apparatus with drive assembly that facilitates reset |
US20030208113A1 (en) | 2001-07-18 | 2003-11-06 | Mault James R | Closed loop glycemic index system |
US6793660B2 (en) | 2001-08-20 | 2004-09-21 | Synthes (U.S.A.) | Threaded syringe for delivery of a bone substitute material |
GB0304823D0 (en) | 2003-03-03 | 2003-04-09 | Dca Internat Ltd | Improvements in and relating to a pen-type injector |
GB0304822D0 (en) | 2003-03-03 | 2003-04-09 | Dca Internat Ltd | Improvements in and relating to a pen-type injector |
DE10326706A1 (de) | 2003-06-04 | 2005-01-05 | Schott Ag | Spritze, insbesondere für medizinische Anwendungen, sowie Verfahren zum Herstellen einer solchen |
DE10327261B4 (de) | 2003-06-17 | 2006-03-02 | Disetronic Licensing Ag | Infusionspumpe und Verfahren zur Überprüfung einer Infusionspumpe |
US20050080384A1 (en) | 2003-10-10 | 2005-04-14 | Green Henry Edward | Illuminating syringe |
DE10350422A1 (de) | 2003-10-29 | 2005-06-16 | Arzneimittel Gmbh Apotheker Vetter & Co. Ravensburg | Verfahren zur Identifizierung und/oder Prüfung und/oder Freigabe von insbesondere vorgefüllten medizinischen Spritzen vor ihrer Anwendung sowie Testvorrichtung zur Durchführung des Verfahrens |
US7771389B2 (en) | 2004-02-17 | 2010-08-10 | Mallinckrodt Inc. | Injector auto purge |
US8808228B2 (en) | 2004-02-26 | 2014-08-19 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
ATE406850T1 (de) | 2004-06-17 | 2008-09-15 | Cadent Ltd | Verfahren und gerät zur farbbildformung einer dreidimensionalen struktur |
ATE452671T1 (de) | 2004-10-21 | 2010-01-15 | Novo Nordisk As | Injektionsvorrichtung mit einem prozessor zur sammlung von ausstossinformationen |
DE102004063664A1 (de) | 2004-12-31 | 2006-07-20 | Tecpharma Licensing Ag | Echtzeitanzeige für eine Vorrichtung zur dosierten Verabreichung eines Produkts |
DE102004063650B4 (de) | 2004-12-31 | 2022-10-20 | Ypsomed Ag | Lebensdaueranzeige für eine Vorrichtung zur dosierten Verabreichung eines Produkts |
DE102004063644A1 (de) | 2004-12-31 | 2006-07-20 | Tecpharma Licensing Ag | Vorrichtung zur dosierten Verabreichung eines fluiden Produkts mit Drehfederantrieb |
US8231573B2 (en) | 2005-02-01 | 2012-07-31 | Intelliject, Inc. | Medicament delivery device having an electronic circuit system |
ATE495775T1 (de) | 2005-05-10 | 2011-02-15 | Novo Nordisk As | Injektionsvorrichtung mit optischem sensor |
WO2007041843A1 (en) | 2005-10-11 | 2007-04-19 | Podaima Blake | Smart medical compliance method and system |
US20070265579A1 (en) | 2006-05-10 | 2007-11-15 | Gennady Kleyman | Dental syringe |
US7996050B2 (en) | 2006-02-28 | 2011-08-09 | Lg Electronics Inc. | Input device for an electronic device and electronic device having the same |
CA2645732C (en) | 2006-03-20 | 2014-12-30 | Novo Nordisk A/S | Electronic module for mechanical medication delivery devices |
CN101421913B (zh) | 2006-04-12 | 2012-07-18 | 诺沃-诺迪斯克有限公司 | 药品传输设备中的可移动安装元件的绝对位置的确定 |
CA2663239C (en) | 2006-09-29 | 2015-03-31 | Novo Nordisk A/S | An injection device with electronic detecting means |
EP2125075A2 (en) | 2007-01-22 | 2009-12-02 | Intelliject, Inc. | Medical injector with compliance tracking and monitoring |
EP2183006B1 (en) | 2007-07-20 | 2019-02-13 | Roche Diabetes Care GmbH | Manually operable portable infusion device |
EP2060284A1 (en) | 2007-11-13 | 2009-05-20 | F.Hoffmann-La Roche Ag | Medical injection device having data input means and a pivotable display |
RU2491965C2 (ru) | 2007-12-31 | 2013-09-10 | Ново Нордиск А/С | Инъекционное устройство со средствами электронного контроля |
US9550031B2 (en) | 2008-02-01 | 2017-01-24 | Reciprocal Labs Corporation | Device and method to monitor, track, map, and analyze usage of metered-dose inhalers in real-time |
US8647309B2 (en) | 2008-05-02 | 2014-02-11 | Sanofi-Aventis Deutschland Gmbh | Medication delivery device |
AU2009286683B2 (en) | 2008-08-29 | 2014-05-01 | Novo Nordisk A/S | Medical injection device with time delay indicator |
EP2349412B1 (en) | 2008-10-01 | 2019-07-24 | Novo Nordisk A/S | Medical assembly with monitoring device |
EP2182456B1 (en) * | 2008-10-28 | 2018-11-28 | Roche Diabetes Care GmbH | A method for monitoring the operation of a medication delivery device, an electronic module, and a medication delivery system |
US8613719B2 (en) | 2008-11-03 | 2013-12-24 | Calibra Medical, Inc. | Dosage sensing unit with tactile feedback |
DK2352536T3 (en) | 2008-11-06 | 2018-06-18 | Novo Nordisk As | Electronically assisted drug delivery device |
CN102256642B (zh) | 2008-12-16 | 2014-09-17 | 松下健康医疗器械株式会社 | 药剂投予装置 |
US8556866B2 (en) | 2009-02-27 | 2013-10-15 | Lifescan, Inc. | Drug delivery system |
US20100286612A1 (en) | 2009-05-06 | 2010-11-11 | William Cirillo | Medication injection supervisor device |
US9950116B2 (en) | 2009-06-01 | 2018-04-24 | Sanofi-Aventis Deutschland Gmbh | Dose setting mechanism for priming a drug delivery device |
US20130123685A1 (en) | 2009-06-03 | 2013-05-16 | Novo Nordisk A/S | Electronically monitored injection device |
US9039655B2 (en) | 2009-11-06 | 2015-05-26 | Crisi Medical Systems, Inc. | Medication injection site and data collection system |
US8394053B2 (en) | 2009-11-06 | 2013-03-12 | Crisi Medical Systems, Inc. | Medication injection site and data collection system |
TWI633902B (zh) | 2010-03-22 | 2018-09-01 | 賽諾菲阿凡提斯德意志有限公司 | 用於判定與醫療裝置有關的資訊之裝置、方法、系統及電腦程式 |
KR101939267B1 (ko) | 2010-07-21 | 2019-01-16 | 삼성전자주식회사 | 주사기의 주사량 측정 장치 및 방법 |
WO2012046199A1 (en) | 2010-10-05 | 2012-04-12 | Hendrik Meiring | Liquid dosage monitoring |
US8520209B2 (en) | 2010-10-14 | 2013-08-27 | Hewlett-Packard Development Company, L.P. | Article, system, and method for color measurement |
JP2012135594A (ja) * | 2010-12-25 | 2012-07-19 | Toshikatsu Hino | 記憶型インスリン注入器 |
WO2012118687A1 (en) | 2011-02-28 | 2012-09-07 | Merck Sharp & Dohme Corp. | Manually operated injector with restricted injection sequence |
WO2012127046A2 (en) | 2011-03-24 | 2012-09-27 | Sanofi-Aventis Deutschland Gmbh | Device and method for detecting an actuation action performable with a medical device |
SG193282A1 (en) * | 2011-03-25 | 2013-10-30 | Sanofi Aventis Deutschland | Dose setting mechanism and injection device |
EP2696918A2 (en) | 2011-04-11 | 2014-02-19 | Novo Nordisk A/S | Injection device incorporating dose monitoring |
EP2729201A1 (en) * | 2011-07-07 | 2014-05-14 | Novo Nordisk A/S | Drug delivery injection pen with add-on dose capturing and display module |
EP2729202B1 (en) | 2011-07-07 | 2018-05-16 | Novo Nordisk A/S | Drug delivery injection pen with add-on dose capturing and display module |
CN104053465A (zh) | 2011-11-18 | 2014-09-17 | 赛诺菲-安万特德国有限公司 | 活塞驱动马达布置 |
TWI631969B (zh) * | 2012-02-13 | 2018-08-11 | 賽諾菲阿凡提斯德意志有限公司 | 安裝於注射裝置的輔助裝置、包含輔助裝置及注射裝置的系統、操作輔助裝置安裝在注射裝置上的方法及電腦程式 |
CN104245020B (zh) * | 2012-02-13 | 2018-04-03 | 赛诺菲-安万特德国有限公司 | 笔式注射装置及其电子夹式模块 |
WO2013120776A1 (en) * | 2012-02-13 | 2013-08-22 | Sanofi-Aventis Deutschland Gmbh | Supplemental device for attachment to an injection device |
CN104203315B (zh) * | 2012-02-13 | 2017-07-25 | 赛诺菲-安万特德国有限公司 | 笔式药物注射装置以及用于监视和记录剂量设定和施用的电子附加监视模块 |
CN104246782B (zh) | 2012-04-17 | 2017-12-29 | 诺和诺德股份有限公司 | 具有方案识别特征的医疗输送装置 |
US8817258B2 (en) * | 2012-05-21 | 2014-08-26 | Common Sensing Inc. | Dose measurement system and method |
EP2692378A1 (en) * | 2012-08-03 | 2014-02-05 | Sanofi-Aventis Deutschland GmbH | Pen-type drug injection device and electronic add-on monitoring module for monitoring and logging dose setting and administration |
US10471213B2 (en) | 2012-08-10 | 2019-11-12 | Sanofi-Aventis Deutschland Gmbh | Pen-type drug injection device and electronic add-on monitoring module for|monitoring and logging dose setting and administration |
WO2014037331A1 (en) | 2012-09-06 | 2014-03-13 | Sanofi-Aventis Deutschland Gmbh | Pen-type drug injection device and electronic add-on monitoring module for monitoring and logging dose setting and administration |
EP2911717B1 (en) * | 2012-10-23 | 2019-05-22 | Insuline Medical Ltd. | Drug dispensing-tracking device, system and method |
KR20140090763A (ko) | 2013-01-10 | 2014-07-18 | 삼성전자주식회사 | 약물 주입기의 주사량 측정 장치 |
DK2945668T3 (en) | 2013-01-15 | 2018-09-03 | Sanofi Aventis Deutschland | ASSEMBLY ASSEMBLY FOR A MEDICAL INJECTION DEVICE FOR GENERATION OF USE REPORTS ON THE USE OF THE DIGITAL IMAGE INJECTION DEVICE |
EP2762184A1 (en) * | 2013-02-05 | 2014-08-06 | Sanofi-Aventis Deutschland GmbH | Drive arrangement for drug dispense device |
CN104981262B (zh) * | 2013-02-19 | 2018-10-09 | 诺和诺德股份有限公司 | 具有轴向开关的旋转传感器模块 |
PL2981312T3 (pl) | 2013-04-05 | 2018-06-29 | Novo Nordisk A/S | Urządzenie zapisujące przystosowane do łączenia dawek |
EP2989785B1 (en) | 2013-04-22 | 2020-04-15 | Sanofi-Aventis Deutschland GmbH | A method of assembling a supplemental device comprising a camera module for an injection pen, and said supplemental device |
JP6758180B2 (ja) | 2013-04-22 | 2020-09-23 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 注射デバイスの使用に関する情報を収集する補助デバイス |
JP6510495B2 (ja) | 2013-05-07 | 2019-05-08 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 注射デバイスへ取り付けるための補足デバイス |
EP3366339B1 (en) | 2013-05-07 | 2020-03-04 | Sanofi-Aventis Deutschland GmbH | An injection device |
US10471216B2 (en) | 2013-07-05 | 2019-11-12 | Sanofi-Aventis Deutschland Gmbh | Apparatus and method for recording the amount of medicament ejected from an injection device |
JP2016538060A (ja) | 2013-11-21 | 2016-12-08 | ノボ・ノルデイスク・エー/エス | 再同期化機構を備えた回転センサモジュール |
US10773032B2 (en) | 2014-03-14 | 2020-09-15 | Shl Medical Ag | Monitoring device |
EP3659651A3 (en) | 2014-07-10 | 2020-10-14 | Companion Medical, Inc. | Medicine administering system including injection pen and companion device |
KR20170035969A (ko) | 2014-08-19 | 2017-03-31 | 케어베이 유럽 리미티드 | 사용자 거동을 로깅 및 추적하기 위한 모션 검출기를 구비한 약물 주입 장치 또는 주입 모형 데모 장치 |
EP3045186A1 (en) | 2015-01-16 | 2016-07-20 | Sanofi-Aventis Deutschland GmbH | Sensor for use with a drug delivery device |
US10737029B2 (en) | 2015-01-21 | 2020-08-11 | Sanofi-Aventis Deutschland Gmbh | Supplemental device for attachment to a pen injector and determination of a set dose amount using optical incremental encoder |
EP3058970A1 (en) | 2015-02-19 | 2016-08-24 | Sanofi-Aventis Deutschland GmbH | Data collection device for attachment to an injection device |
WO2016135236A1 (en) | 2015-02-27 | 2016-09-01 | Novo Nordisk A/S | Accessory device with mounting safety feature |
MX2017015280A (es) | 2015-05-29 | 2018-05-15 | Insulcloud S L | Dispositivo de monitorizacion para la aplicacion de un farmaco con una pluma de farmaco, con registro, comunicacion y alarmas. |
EP4316552A3 (en) | 2015-06-09 | 2024-04-17 | Sanofi-Aventis Deutschland GmbH | Data collection apparatus for attachment to an injection device |
EP3184137A1 (en) | 2015-12-23 | 2017-06-28 | Carebay Europe Ltd. | Medicament delivery device with user feedback capability |
US20170182258A1 (en) | 2015-12-29 | 2017-06-29 | InsuLog Ltd. | Adjunct device and system for an injector for monitoring injected amounts |
EP3432949B1 (en) | 2016-03-25 | 2024-05-01 | Eli Lilly and Company | Determination of a dose set and delivered in a medication delivery device |
US20190269858A1 (en) | 2018-03-05 | 2019-09-05 | Verily Life Sciences Llc | Multi-channel rotary encoder |
-
2016
- 2016-06-09 EP EP23208919.3A patent/EP4316552A3/en active Pending
- 2016-06-09 CN CN201680034135.7A patent/CN107787236B/zh active Active
- 2016-06-09 CN CN202010923858.0A patent/CN112206381B/zh active Active
- 2016-06-09 EP EP16729241.6A patent/EP3307357B2/en active Active
- 2016-06-09 WO PCT/EP2016/063139 patent/WO2016198516A1/en active Application Filing
- 2016-06-09 JP JP2017564021A patent/JP6901975B2/ja active Active
- 2016-06-09 PL PL16729241.6T patent/PL3307357T5/pl unknown
- 2016-06-09 CN CN202110567914.6A patent/CN113456946B/zh active Active
- 2016-06-09 HU HUE16729241A patent/HUE050055T2/hu unknown
- 2016-06-09 EP EP19209180.9A patent/EP3656423B1/en active Active
- 2016-06-09 US US15/579,656 patent/US10874802B2/en active Active
- 2016-06-09 DK DK16729241.6T patent/DK3307357T4/da active
- 2016-06-09 ES ES16729241T patent/ES2805230T5/es active Active
-
2018
- 2018-06-26 HK HK18108168.9A patent/HK1248622A1/zh unknown
-
2020
- 2020-01-14 US US16/742,219 patent/US11439762B2/en active Active
- 2020-07-24 US US16/938,433 patent/US11730891B2/en active Active
- 2020-08-24 US US17/001,065 patent/US11944796B2/en active Active
-
2021
- 2021-03-10 JP JP2021037904A patent/JP7162093B2/ja active Active
- 2021-09-16 US US17/477,108 patent/US11511047B2/en active Active
-
2023
- 2023-04-20 US US18/137,138 patent/US20230256175A1/en active Pending
- 2023-11-08 US US18/504,657 patent/US20240066234A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6901975B2 (ja) | 注射デバイスに取り付けられるデータ収集装置 | |
CN112584884B (zh) | 用于附接至注射装置的数据收集设备 | |
US20240058545A1 (en) | Dosage measurement system | |
JP7203098B2 (ja) | 薬剤投与デバイスおよびデータ収集デバイス | |
CN116056741A (zh) | 用于药物递送装置的电子系统、药物递送装置和相关方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190603 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200518 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200609 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200909 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20201110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210310 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20210310 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20210323 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20210507 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20210518 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210601 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210618 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6901975 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |